Nurix Therapeutics, Inc. (NRIX) insider trading

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Christine Ring

Chief Legal Officer

—

$6.64M (83) scheduled

−$6.64M

4,406

0.0040%

$71.39K

+8.8%

Houte Hans van

Chief Financial Officer

—

$4.77M (48) scheduled

−$4.77M

42,745

0.0391%

$692.55K

—

Pierre Beaurang

Chief Business Officer

—

$1.84M (21) scheduled

−$1.84M

120,996

0.1108%

$1.96M

+3.7%

Gwenn Hansen

Chief Scientific Officer

—

$1.63M (45) scheduled

−$1.63M

123,452

0.1130%

$2.00M

+2,586%

Julia P Gregory

Director

—

$528.53K (1) scheduled

−$528.53K

10,750

0.0098%

$174.17K

—

Stefani Wolff

EVP and COO

—

$22.34K (5)

−$22.34K

6,113

0.0056%

$99.04K

+96.9%

Third Rock Ventures III, L.P. entity

10% owner

—

3,509,348

3.21%

$56.86M

+3,943%

Column Group L P entity

10% owner

—

2,080,607

1.90%

$33.71M

—

Redmile Group, LLC entity

10% owner

—

1,176,470

1.08%

$19.06M

—

Wellington Biomedical Innovation Master Investors (Cayman) I L.P.

10% owner

—

784,313

0.7179%

$12.71M

—

Robert Tjian

Director

—

124,999

0.1144%

$2.03M

+275.0%

Lori Anne Kunkel

Director

—

0

0.0000%

$0.00

−100.0%

Nurix Therapeutics, Inc.

What the insiders did Mostly scheduled

By person